Clinical Trial Update: A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. [Phase 2]

View source ↗

Summary

Phase II trial evaluating neoadjuvant TCH and TCHL regimens in HER-2 positive breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Lapatinib (Lapatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED